Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101640 | 1.00 | MEN1 (0.62) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL18230266 | 0.93 | MEN1 (0.66) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL18230267 | 0.93 | MEN1 (0.66) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL4733033 | 0.93 | MEN1 (0.68) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL5888030 | 0.86 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL5888033 | 0.86 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTCA1 | |
| SCHEMBL31615446 | 0.85 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTTHRB | |
| SCHEMBL6166918 | 0.85 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTTHRB | |
| SCHEMBL4122520 | 0.85 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTTHRB | |
| SCHEMBL2244455 | 0.84 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ABBOT PHILIP | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ADORA3, ADORA1, P2RX1 | MEN1 867/4885KMT2A 1517/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.